Panel Meeting Solesta(TM) December 2, 2010

Q-Med AB submitted in April, 2010, together with its partner Oceana
Therapeutics, a Premarket Approval (PMA) application for Solesta(TM) in the US.
The PMA will be discussed on December 2, 2010, at a public meeting of the FDA's
Gastroenterology and Urology Devices Panel. The panel is expected to address
specific concerns or questions the FDA may seek guidance on for the continued
review process of the Solesta PMA application, a product indicated for the
treatment of fecal incontinence.


For more information please visit: www.oceanathera.com

Queries should be addressed to:
Alexander Kotsinas, Vice President and CFO
Tel: +46 73 500 1111

Per Langö, Director Corporate Development
Tel: +46 73 387 15 21


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web:
www.q-med.com.



[HUG#1445000]